Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

<p>Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis</p>
Rhea Singh, Courtney E. Heron, Rima I. Ghamrawi, et al.
ImmunoTargets and Therapy (2020) Vol. Volume 9, pp. 255-272
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
Lisa A. Beck, Michael J. Cork, Masayuki Amagai, et al.
JID Innovations (2022) Vol. 2, Iss. 5, pp. 100131-100131
Open Access | Times Cited: 140
Natural Sources of Therapeutic Agents Used in Skin Conditions
Monica Dinu, Alin Laurențiu Tatu, Dorin Ioan Cocoș, et al.
Life (2024) Vol. 14, Iss. 4, pp. 492-492
Open Access | Times Cited: 24
The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review
Aikaterini Tsiogka, Maria Kyriazopoulou, George Kontochristopoulos, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4431-4431
Open Access | Times Cited: 53
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 1, pp. 172-181
Open Access | Times Cited: 38
Interplay of cytokines in the pathophysiology of atopic dermatitis: insights from Murin models and human
Y Yamamura, Chisa Nakashima, Atsushi Otsuka
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 11
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
Yan Zhao, Litao Zhang, Yangfeng Ding, et al.
American Journal of Clinical Dermatology (2021) Vol. 22, Iss. 6, pp. 877-889
Open Access | Times Cited: 43
Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis
Patrick O. Perche, Madison K. Cook, Steven R. Feldman
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 1, pp. 86-98
Closed Access | Times Cited: 35
Terminalia chebula Retz. extract ameliorates the symptoms of atopic dermatitis by regulating anti-inflammatory factors in vivo and suppressing STAT1/3 and NF-ĸB signaling in vitro
Hye Jin Kim, Hyun‐Kyung Song, Sun Haeng Park, et al.
Phytomedicine (2022) Vol. 104, pp. 154318-154318
Closed Access | Times Cited: 28
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
Miguel Nogueira, Tiago Torres
Dermatology Practical & Conceptual (2021), pp. e2021145-e2021145
Open Access | Times Cited: 34
Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis
Farnam Barati Sedeh, Mattias A. S. Henning, Gregor B. E. Jemec, et al.
Acta Dermato Venereologica (2022) Vol. 102, pp. adv00764-adv00764
Open Access | Times Cited: 23
Epicutaneous Sensitization and Food Allergy: Preventive Strategies Targeting Skin Barrier Repair—Facts and Challenges
Anna Dębińska, Barbara Sozańska
Nutrients (2023) Vol. 15, Iss. 5, pp. 1070-1070
Open Access | Times Cited: 14
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)
Jonathan I. Silverberg, Bruce Strober, Brian A. Feinstein, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 153, Iss. 4, pp. 1040-1049.e12
Closed Access | Times Cited: 13
Diagnosis and Management of Dermatitis, Including Atopic, Contact, and Hand Eczemas
Cynthia X. Chan, Kathryn A. Zug
Medical Clinics of North America (2021) Vol. 105, Iss. 4, pp. 611-626
Closed Access | Times Cited: 29
New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression
Anna Dębińska
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2506-2506
Open Access | Times Cited: 29
Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
Fatemeh Zabihi, Mariam Cherri, Xiao Guo, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 1, pp. 77-77
Open Access | Times Cited: 4
Novel drug delivery systems in topical treatment of atopic dermatitis
Meghna Dabhadkar, Madhur Kulkarni
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges
Celina Dubin, Ester Del Duca, Emma Guttman‐Yassky
Therapeutics and Clinical Risk Management (2020) Vol. Volume 16, pp. 1319-1332
Open Access | Times Cited: 30
Itch and Sleep Improvements with Baricitinib in Patients with Atopic Dermatitis: A Post Hoc Analysis of 3 Phase 3 Studies
Timo Buhl, David Rosmarin, E. Serra‐Baldrich, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 3, pp. 971-982
Open Access | Times Cited: 21
Cosmetic Applications of Bee Venom
Aida A. Abd El‐Wahed, Shaden A. M. Khalifa, Mohamed H. Elashal, et al.
Toxins (2021) Vol. 13, Iss. 11, pp. 810-810
Open Access | Times Cited: 20
The evolving atopic dermatitis management landscape
Vikram N. Sahni, Esther A. Balogh, Lindsay C. Strowd, et al.
Expert Opinion on Pharmacotherapy (2021) Vol. 23, Iss. 4, pp. 517-526
Closed Access | Times Cited: 17
Dupilumab with concomitant Janus kinase inhibitor: a novel treatment strategy for atopic dermatitis with poor response to dupilumab
Nali Yang, Lele Chen, Junyi Shao, et al.
British Journal of Dermatology (2022) Vol. 187, Iss. 5, pp. 828-830
Open Access | Times Cited: 12
Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis
Mohammad I. Fardos, Rohan Singh, Patrick O. Perche, et al.
Expert Review of Clinical Immunology (2021) Vol. 18, Iss. 3, pp. 221-231
Closed Access | Times Cited: 13
Dermatologic conditions in skin of color compared to white patients: similarities, differences, and special considerations
Sheena Chatrath, Laurence A. Bradley, Joshua B. Kentosh
Archives of Dermatological Research (2022)
Closed Access | Times Cited: 8
How to Understand Personalized Medicine in Atopic Dermatitis Nowadays?
Alicja Mesjasz, Karol Kołkowski, Andreas Wollenberg, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7557-7557
Open Access | Times Cited: 4
Oral Bacterial Lysate OM-85: Advances in Pharmacology and Therapeutics
Lingling Zhu, Yanhong Wang, Jianhua Feng, et al.
Drug Design Development and Therapy (2024) Vol. Volume 18, pp. 4387-4399
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top